Briffa R, Langdon SP, Grech G, Harrison DJ. Acquired and intrinsic resistance to colorectal cancer treatment. In: Colorectal cancer-diagnosis, screening and managemented. London: Intech Open; 2018. p. 57–81.

Google Scholar 

Lu Q, Kou D, Lou S, Ashrafizadeh M, Aref AR, Canadas I, et al. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. J Hematol Oncol. 2024;17:16.

Article  PubMed  PubMed Central  Google Scholar 

Zhao S, Tang Y, Wang R, Najafi M. Mechanisms of cancer cell death induction by paclitaxel: an updated review. Apoptosis. 2022;27:647–67.

Article  CAS  PubMed  Google Scholar 

Zhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 2019;24:40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu Y, Wang A, Zhang S, Kim J, Xia J, Zhang F, et al. Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells. J Adv Res. 2023;49:159–73.

Article  CAS  PubMed  Google Scholar 

Harbeck N. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. Breast (Edinburgh, Scotland). 2022;62(Suppl 1):S12–6.

Article  PubMed  Google Scholar 

Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updates. 2021;54: 100742.

Article  CAS  Google Scholar 

Chen Q, Xu S, Liu S, Wang Y, Liu G. Emerging nanomedicines of paclitaxel for cancer treatment. J Control Release. 2022;342:280–94.

Article  CAS  PubMed  Google Scholar 

Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677–81.

Article  PubMed  PubMed Central  Google Scholar 

Ismail U, Killeen RB. Taxane Toxicity. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Robert Killeen declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.; 2024.

Das T, Anand U, Pandey SK, Ashby CR Jr, Assaraf YG, Chen ZS, et al. Therapeutic strategies to overcome taxane resistance in cancer. Drug Resist Updates. 2021;55: 100754.

Article  CAS  Google Scholar 

Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomed Nanotechnol Biol Med. 2016;12:655–64.

Article  CAS  Google Scholar 

Škubník J, Svobodová Pavlíčková V, Ruml T, Rimpelová S. Autophagy in cancer resistance to paclitaxel: development of combination strategies. Biomed Pharmacother. 2023;161:114458.

Article  PubMed  Google Scholar 

Gao W, Bigham A, Ghomi M, Zarrabi A, Rabiee N, Saeb MR, et al. Micelle-engineered nanoplatforms for precision oncology. Chem Eng J. 2024;495: 153438.

Article  CAS  Google Scholar 

Niu X, You Q, Hou K, Tian Y, Wei P, Zhu Y, et al. Complex roles of autophagy in cancer development, immune evasion, and drug resistance. Drug Resist Updates. 2024;78: 101170.

Article  Google Scholar 

Yang Y, Liu L, Tian Y, Gu M, Wang Y, Ashrafizadeh M, et al. Autophagy-driven regulation of cisplatin response in human cancers: exploring molecular and cell death dynamics. Cancer Lett. 2024;587: 216659.

Article  CAS  PubMed  Google Scholar 

Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, et al. Paclitaxel and docetaxel resistance in prostate cancer: molecular mechanisms and possible therapeutic strategies. Biomed Pharmacother. 2023;160: 114392.

Article  CAS  PubMed  Google Scholar 

Lin ZX, Zhu LH, Huang JY, Huang YY, Lin X. Paclitaxel-resistant related lncRNA DBH-AS1 promotes the proliferation and invasion of esophageal cancer. Eur Rev Med Pharmacol Sci. 2022;26:8903–13.

PubMed  Google Scholar 

Shi C, Ren S, Zhao X, Li Q. lncRNA MALAT1 regulates the resistance of breast cancer cells to paclitaxel via the miR-497-5p/SHOC2 axis. Pharmacogenomics. 2022;23:973–85.

Article  CAS  PubMed  Google Scholar 

Wei X, Tao S, Mao H, Zhu H, Mao L, Pei W, et al. Exosomal lncRNA NEAT1 induces paclitaxel resistance in breast cancer cells and promotes cell migration by targeting miR-133b. Gene. 2023;860: 147230.

Article  CAS  PubMed  Google Scholar 

Zhao Y, Hong L. lncRNA-PRLB confers paclitaxel resistance of ovarian cancer cells by regulating RSF1/NF-κB signaling pathway. Cancer Biother Radiopharm. 2021;36:202–10.

PubMed  Google Scholar 

Zheng S, Fu W, Huang Q, Zhou J, Lu K, Gu J, et al. LncRNA PRKCQ-AS1 regulates paclitaxel resistance in triple-negative breast cancer cells through miR-361-5p/PIK3C3 mediated autophagy. Clin Exp Pharmacol Physiol. 2023;50:431–42.

Article  CAS  PubMed  Google Scholar 

Hashemi M, Moosavi MS, Abed HM, Dehghani M, Aalipour M, Heydari EA, et al. Long non-coding RNA (lncRNA) H19 in human cancer: from proliferation and metastasis to therapy. Pharmacol Res. 2022;184: 106418.

Article  CAS  PubMed  Google Scholar 

Xu J, Xu Y, Ye G, Qiu J. LncRNA-SNHG1 promotes paclitaxel resistance of gastric cancer cells through modulating the miR-216b-5p-hexokianse 2 axis. J Chemother (Florence, Italy). 2023;35:527–38.

Article  CAS  Google Scholar 

Zhao H, Wang A, Zhang Z. LncRNA SDHAP1 confers paclitaxel resistance of ovarian cancer by regulating EIF4G2 expression via miR-4465. J Biochem. 2020;168:171–81.

Article  CAS  PubMed  Google Scholar 

Li Y, Wang Y, Wang H, Zhang L, Ding Y, Chen S, et al. Effects of lncRNA RP11–770J1.3 and TMEM25 expression on paclitaxel resistance in human breast cancer cells. J Zhejiang Univ Med Sci. 2017;46:364–70.

Google Scholar 

Jiang J, Wang S, Wang Z, Cai J, Han L, Xie L, et al. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer. Cancer Chemother Pharmacol. 2020;86:295–305.

Article  CAS  PubMed  Google Scholar 

Wang H, Zhou Y, Zhang S, Qi YA, Wang M. PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis. Oncol Res. 2021;29:275–89.

Article  PubMed  Google Scholar 

Wang R, Zhang T, Yang Z, Jiang C, Seng J. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1. J Cell Mol Med. 2018;22:4068–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Yang X, Gao S, Wen M, Yu Q. DDX11-AS1 modulates DNA damage repair to enhance paclitaxel resistance of lung adenocarcinoma cells. Pharmacogenomics. 2023;24:163–72.

Article  CAS  PubMed  Google Scholar 

Luo F, Zhang M, Sun B, Xu C, Yang Y, Zhang Y, et al. LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling. Mol Cancer. 2024;23:60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X-W, Bu P, Liu L, Zhang X-Z, Li JJB. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophy Res Commun. 2015;462:227–32.

Article  CAS  Google Scholar 

Liu E, Liu Z, Zhou Y, Mi R, Wang DJIjoc,. Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. Int J Clin Exp Med. 2015;8:20565.

CAS  PubMed  PubMed Central  Google Scholar 

Li J, Yang S, Su N, Wang Y, Yu J, Qiu H, et al. Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/β-catenin pathway in human ovarian cancer. Tumor Biol. 2016;37:2057–65.

Article  CAS  Google Scholar 

Özeş AR, Miller DF, Özeş ON, Fang F, Liu Y, Matei D, et al. NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer. Oncogene. 2016;35:5350–61.

Article  PubMed